New tests could transform care for rare kidney diseases

NCT ID NCT05985122

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to develop better lab tests to diagnose and monitor two rare kidney diseases: atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G). Researchers will analyze blood, cells, and kidney tissue from 180 patients and healthy volunteers to find markers that help classify the disease and guide treatment. The goal is to make diagnosis more accurate and personalize care with existing or new drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atypical hemolytic-uremic syndrome complement 3 glomerulopathy hemolytic-uremic syndrome membranoproliferative glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centro di Ricerche Cliniche per le Malattie Rare "Aldo e Cele Daccò"

    Ranica, BG, 24020, Italy